Background: GRACE, TIMI, Zwolle, and CADILLAC are risk scores designed for predicting short-term outcome after acute coronary syndromes. The aim of our study was to test their utility for a prognosis of 5-year survival in a "real-life" population of patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI).
Methods: Our registry consisted of consecutive patients with STEMI treated with pPCI. Five-year follow-up was performed with all-cause mortality as the end-point.
Results: Out of 505 patients (mean age 58.6±11.3 years) 32 died during the first 30 days (6.3%) and an additional 74 within 5 years (15.6%). PCI was successful in 95.2% (n=481). Prognostic values (c statistics) for predicting 5-year mortality equaled: 0.742 (CI 0.69-0.79) for the GRACE risk score, 0.727 (CI 0.67-0.78) for TIMI, 0.72 (CI 0.67-0.77) for Zwolle, and 0.687 (CI 0.63-0.74) for CADILLAC. In a univariate analysis all the scores were associated with the 5-year outcome.
Conclusions: GRACE, TIMI, and Zwolle risk scores predicted well 5-year all-cause mortality in patients with STEMI treated with pPCI. Our data show that the usefulness of initial bedside risk assessment can be further extended for long-term follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2009.10.026 | DOI Listing |
Arq Bras Cardiol
January 2025
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brasil.
Background: Acute coronary syndrome (ACS) is one of the leading causes of mortality worldwide. Knowing the predisposing factors is essential for preventing it.
Objectives: To describe the etiological and epidemiological characteristics of the population with ACS admitted to an emergency room in the State of São Paulo.
Cureus
November 2024
Interventional Cardiology Department, Lady Reading Hospital, Peshawar, PAK.
Background: Primary percutaneous coronary intervention (PCI) is crucial in managing acute ST-segment elevation myocardial infarction (STEMI), emphasizing the importance of optimal myocardial reperfusion.
Objective: The goal of this research was to determine how loading doses of rosuvastatin and atorvastatin affected the flow rate of thrombolysis in myocardial infarction (TIMI) immediately post-perfusion thrombolysis in patients undergoing primary PCI.
Methodology: This prospective, comparative study was carried out over a one-year period (January 2023 to December 2023) in Pakistan.
Am J Cardiovasc Drugs
December 2024
Cardiovascular Institute, Detroit Medical Center, Heart Hospital, Wayne State University, 311 Mack Ave, Detroit, MI, 48201, USA.
Background: Morphine is used to control pain in ST-elevation myocardial infarction but reduces P2Y12 inhibition. It is not known if this modulation of platelet inhibition appreciably affects clinical outcomes.
Methods: We screened 979 articles and identified seven studies that met the eligibility criteria for meta-analysis.
J Am Soc Echocardiogr
December 2024
MIRACL.ai laboratory, Multimodality Imaging for Research and Analysis Core Laboratory and Artificial Intelligence, University Hospital of Lariboisiere (AP-HP), 75010, Paris, France; Université Paris Cité, Service de Cardiologie, Hôpital Lariboisière - Assistance Publique des Hôpitaux de Paris (APHP), Inserm UMRS 942, 75010, Paris, France. Electronic address:
SAGE Open Med Case Rep
December 2024
Cardiology A Department, Ibn Sina University Hospital Center, Rabat, Morocco.
Traditionally reflecting critical stenosis of the proximal left anterior descending (LAD) artery, Wellens' syndrome (WS) is an electrocardiogram (ECG) pattern of biphasic or deeply inverted T waves in leads V2 and V3. This critical stenosis can progress to an extensive anterior myocardial infarction (MI) if early and appropriate management is not received promptly. The diagnosis of severe stenosis of the LAD coronary artery can be made by using electrocardiographic changes in Wellens' syndrome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!